Lack of association between cancer history and PARKIN genotype: A family based study in PARKIN/Parkinson's Families

Genes Chromosomes and Cancer

Volumn 51, Issue 12, 2012, Pages 1109-1113

  Alcalay, Roy N ^a   Clark, Lorraine N ^a,b,c   Marder, Karen S ^a   Bradley, W Edward C ^d,e,f  

^a Columbia University ^*  (United States)

^b Department of Pathology and Cell Biology ^*  (United States)

^c Flemish Institute for Biotechnology   (United States)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f Institut du Cancer de Montreal   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PARKIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOSOMAL RECESSIVE INHERITANCE; BREAST CANCER; CANCER INHIBITION; CANCER RISK; COLON CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FAMILY STUDY; FEMALE; GENE DELETION; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC SCREENING; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MELANOMA; MOUSE; MUTATION RATE; NONHUMAN; ONSET AGE; PARKINSON DISEASE; POINT MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER;

AGE OF ONSET; AGED; ANIMALS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MICE; MIDDLE AGED; NEOPLASMS; PARKINSON DISEASE; UBIQUITIN-PROTEIN LIGASES;

MUS;

EID: 84867233572     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.21995     Document Type: Article

References (24)

1. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Ross BM, Verbitsky M, Kisselev S, Louis ED, Comella C, Colcher A, Jennings D, Nance MA, Bressman SB, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Ottman R, Marder K, Clark LN. 2010. Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. Arch Neurol 67: 1116-1122.
2. Alderton GK. 2010. Tumour progression: Disease connections. Nat Rev Cancer 10: 663.
3. Bignell GR, Greenman CD, Davies H, Butler AP, Edkins S, Andrews JM, Buck G, Chen L, Beare D, Latimer C, Widaa S, Hinton J, Fahey C, Fu B, Swamy S, Dalgliesh GL, Teh BT, Deloukas P, Yang F, Campbell PJ, Futreal PA, Stratton MR. 2010. Signatures of mutation and selection in the cancer genome. Nature 463: 893-898.
4. Bradley WE, Di Paola D, Rampakakis E, Zannis-Hadjopoulos M. 2010a. More is less: inactivation and deletion events and the search for tumor suppressor genes. J Cell Biochem 110: 281-287.
5. Bradley WE, Raelson JV, Dubois DY, Godin E, Fournier H, Privé C, Allard R, Pinchuk V, Lapalme M, Paulussen RJ, Belouchi A. 2010b. Hotspots of large rare deletions in the human genome. PLoS One 5: e9401.
6. Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, McAdams H, Trapasso F, Drusco A, Shimizu M, Masciullo V, D'Andrilli G, Scambia G, Picchio MC, Alder H, Godwin AK, Croce CM. 2003. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci USA 100: 5956-5961.
7. Denison SR, Wang F, Becker NA, Schüle B, Kock N, Phillips LA, Klein C, Smith DI. 2003. Alterations in the common fragile site gene Parkin in ovarian and other cancers. Oncogene 22: 8370-8378.
8. Fujiwara M, Marusawa H, Wang HQ, Iwai A, Ikeuchi K, Imai Y, Kataoka A, Nukina N, Takahashi R, Chiba T. 2008. Parkin as a tumor suppressor gene for hepatocellular carcinoma. Oncogene 27: 6002-6011.
9. Garber K. 2010. Parkinson's disease and cancer: The unexplored connection. J Natl Cancer Inst 102: 371-374.
10. Kay DM, Stevens CF, Hamza TH, Montimurro JS, Zabetian CP, Factor SA, Samii A, Griffith A, Roberts JW, Molho ES, Higgins DS, Gancher S, Moses L, Zareparsi S, Poorkaj P, Bird T, Nutt J, Schellenberg GD, Payami H. 2010. A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2. Neurology 75: 1189-1194.
11. Klein BE, Lee KE, Moss SE, Trentham-Dietz A, Klein R. 2010. Self- and registry-reported cancer in a population-based longitudinal study. WMJ 109:261-266.
12. Lee JS, Grisham JW, Thorgeirsson SS. 2005. Comparative functional genomics for identifying models of human cancer. Carcinogenesis 26: 1013-1020.
13. Luongo C, Moser AR, Gledhill S, Dove WF. 1994. Loss of Apc+ in intestinal adenomas from Min mice. Cancer Res 54: 5947-5952.
14. Mao JH, Perez-Losada J, Wu D, Delrosario R, Tsunematsu R, Nakayama KI, Brown K, Bryson S, Balmain A. 2004. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature 432: 775-779.
15. Marder KS, Tang MX, Mejia-Santana H, Rosado L, Louis ED, Comella CL, Colcher A, Siderowf AD, Jennings D, Nance MA, Bressman S, Scott WK, Tanner CM, Mickel SF, Andrews HF, Waters C, Fahn S, Ross BM, Cote LJ, Frucht S, Ford B, Alcalay RN, Rezak M, Novak K, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Neils GD, Verbitsky M, Kisselev S, Caccappolo E, Ottman R, Clark LN. 2010. Predictors of parkin point mutations in early-onset Parkinson disease: The consortium on risk for early-onset Parkinson disease study. Arch Neurol 67: 731-738
16. Perez FA, Palmiter RD. 2005. Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci USA 102: 2174-2179.
17. Picchio MC, Martin ES, Cesari R, Calin GA, Yendamuri S, Kuroki T, Pentimalli F, Sarti M, Yoder K, Kaiser LR, Fishel R, Croce CM. 2004. Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer. Clin Cancer Res 10: 2720-2724.
18. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, Varela I, Lin ML, Ordóñez GR, Bignell GR, Ye K, Alipaz J, Bauer MJ, Beare D, Butler A, Carter RJ, Chen L, Cox AJ, Edkins S, Kokko-Gonzales PI, Gormley NA, Grocock RJ, Haudenschild CD, Hims MM, James T, Jia M, Kingsbury Z, Leroy C, Marshall J, Menzies A, Mudie LJ, Ning Z, Royce T, Schulz-Trieglaff OB, Spiridou A, Stebbings LA, Szajkowski L, Teague J, Williamson D, Chin L, Ross MT, Campbell PJ, Bentley DR, Futreal PA, Stratton MR. 2010a. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463: 191-196.
19. Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, Jones D, Lin ML, Beare D, Lau KW, Greenman C, Varela I, Nik-Zainal S, Davies HR, Ordoñez GR, Mudie LJ, Latimer C, Edkins S, Stebbings L, Chen L, Jia M, Leroy C, Marshall J, Menzies A, Butler A, Teague JW, Mangion J, Sun YA, McLaughlin SF, Peckham HE, Tsung EF, Costa GL, Lee CC, Minna JD, Gazdar A, Birney E, Rhodes MD, McKernan KJ, Stratton MR, Futreal PA, Campbell PJ. 2010b. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463: 184-190.
20. Poulogiannis G, McIntyre RE, Dimitriadi M, Apps JR, Wilson CH, Ichimura K, Luo F, Cantley LC, Wyllie AH, Adams DJ, Arends MJ. 2010. PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci USA 107: 15145-15150.
21. Schouten LJ, Straatman H, Kiemeney LA, Verbeek AL. 1994. Cancer incidence: life table risk versus cumulative risk. J Epidemiol Community Health. 48:596-600.
22. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE. 2006. The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274.
23. Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W, Ladanyi M, Sander C, Heguy A, Holland EC, Paty PB, Mischel PS, Liau L, Cloughesy TF, Mellinghoff IK, Solit DB, Chan TA. 2010. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet 42: 77-82.
24. Welcker M, Clurman BE. 2008. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 8: 83-93.